logo

For the Inventor, By the Inventor

Cambridge, United Kingdom

Kymab Limited


USPTO Granted Patents = 105


Trademarks = 2

Forward Citations = 1,002

Loading Chart...
Loading Chart...

72 inventors (with patents filed for the assignee):

goldMedal Jasper Clube (54 out of 55 patents)

silverMedal E-Chiang Lee (42 out of 42 patents)

bronzeMedal Allan Bradley (33 out of 47 patents)

4.  Qi Liang (24 out of 24 patents)

5.  Wei Wang (22 out of 39 patents)

6.  Ian Kirby (22 out of 27 patents)

7.  Jamie Iain Campbell (22 out of 26 patents)

8.  Miha Kosmac (21 out of 21 patents)

9.  Steve Holmes (15 out of 27 patents)

10.  Hui Liu (12 out of 12 patents)

11.  Dominik Spensberger (11 out of 11 patents)

12.  Volker Germaschewski (10 out of 10 patents)

13.  Glenn A Friedrich (10 out of 54 patents)

14.  Cassandra Van Krinks (8 out of 8 patents)

15.  Thomas Gallagher (7 out of 7 patents)


Core Competencies:
Anti-CD7 Antibodies
ICOS Antibodies
PCSK9 Antagonists
Anti-PD-L1 Antibodies
Bispecific Antibodies
Transgenic Non-Human Vertebrates
Precision Medicine
Anti-OX40L Antibodies
Immunoglobulin Gene Diversity
Therapeutic Molecules
Animal Models
Neurodegenerative Diseases

105 patents:

1. 12473378 - ANTIGEN-BINDING MOLECULES COMPRISING UNPAIRED VARIABLE DOMAINS (2025-11-18),
2. 12473371 - ANTI-OPG ANTIBODIES (2025-11-18),
3. 12435134 - Antagonists anti-CD7 antibodies (2025-10-07),
4. 12404330 - Antibodies to ICOS (2025-09-02),
5. 12384855 - PCSK9 antagonists (2025-08-12),
6. 12209128 - Anti-PD-L1 antibodies (2025-01-28),
7. 11976135 - FIXaxFX bispecific antibody with common light chain (2024-05-07),
8. 11965026 - Anti-PD-L1 and IL-2 cytokines (2024-04-23),
9. 11920128 - Methods, cells and organisms (2024-03-05),
10. 11919969 - Bispecific antibodies for factor IX and factor X (2024-03-05),
11. 11878048 - Use of the extracellular domain of transferrin receptor 2 for the diagnosis and treatment of primary or secondary sclerosing diseases (2024-01-23),
12. 11858996 - Anti-ICOS antibodies (2024-01-02),
13. 11820810 - Antibodies, variable domains and chains tailored for human use (2023-11-21),
14. 11812731 - Animal models and therapeutic molecules (2023-11-14),
15. 11779604 - Antibodies, combinations comprising antibodies, biomarkers, uses and methods (2023-10-10),
Kymab is a biotechnology company specializing in the discovery and development of fully human monoclonal antibodies. With a proprietary technology platform called Kymouse, Kymab is able to deliver a diverse and optimized pipeline of novel biologic medicines. The company collaborates with pharmaceutical partners to further advance and commercialize its therapeutic antibodies.
This text is generated by artificial intelligence and may not be accurate.

logo

Company Badge

USPTO Data Jan 1 1976 - Jan 20 2026

...
105 Patents

#10 in Cambridge

#165 in United Kingdom

#7,271 in the World

...
Cambridge, United Kingdom

Kymab Limited

Forward Citations = 1,002

72 inventors:

goldMedal Jasper Clube (54 out of 55 patents)

silverMedal E-Chiang Lee (42 out of 42 patents)

bronzeMedal Allan Bradley (33 out of 47 patents)

4.  Qi Liang (24 out of 24 patents)

5.  Wei Wang (22 out of 39 patents)

Please report any incorrect information to support@idiyas.com
Loading…